3rd-generation EGFR tyrosine-kinase inhibitor
Osimertinib (Specialist drug)
Brand names: Tagrisso
Adult dose
Dose: Specialist initiation only — refer to BNF/SmPC; usually 80mg OD
Route: PO
Frequency: OD
Clinical pearls
- EGFR T790M-positive metastatic NSCLC; first-line EGFR-mutated NSCLC; specialist oncology
Contraindications
- See SmPC
Side effects
- ILD/pneumonitis (potentially fatal)
- QT prolongation
- Cardiomyopathy
- Diarrhoea
- Rash
- Stomatitis
- Cytopenias
Interactions
- Strong CYP3A4 inducers
- QT-prolonging drugs
Monitoring
- LFTs
- ECG
- Echo (LVEF)
- Pulmonary symptoms
Reference: BNF; NICE TA416/TA653; SmPC; https://bnf.nice.org.uk/drugs/osimertinib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Tisdale Risk Score for QT Prolongation · Arrhythmia
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy